Enterocolitis severa secundaria a ipilimumab y nivolumab con excelente respuesta a dosis única de infliximab

Luque Carmona, Ana María; Ontanilla-Clavijo, Guillermo; Carnerero, Eduardo Leo.
Rev. esp. enferm. dig ; 112(11): 889-890, nov. 2020. ilus
Artículo en Español | IBECS (España) | ID: ibc-198782

Documentos relacionados

  1. Severe enterocolitis secondary to ipilimumab and nivolumab with an excellent response to a single dose of infliximab.
  2. Relatlimab and nivolumab in the treatment of melanoma.
  3. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.
  4. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
  5. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
  6. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
  7. Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab.
  8. Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series.
  9. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
  10. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.